Lazar Popovic, Head of Clinic for Medical Oncology at Oncology Institute of Vojvodina, shared on LinkedIn:
“Last three days I had a privilege to take part in another great eXIOME meeting organized by AROME group. This year we discussed on optimal perioperative therapies for different cancers in low and middle income countries.
My roles were to chair HR+/HER2- negative breast cancer session and to lead a panel discussion together with Karima Oualla on bladder cancer.
Big thanks and congratulations to AROME leaders Yazid Belkacemi and Joseph Gligorov for great program and organization.”
About eXIOME 2026
EXIOME 2026 (Expert International Oncology Meeting) has established itself as a vital international platform dedicated to discussing advanced oncology practices, emerging clinical data, and the practical challenges of cancer care implementation across diverse healthcare landscapes. The 3rd edition focused heavily on addressing regional disparities in cancer survival by analyzing how breakthrough therapies and global guidelines can be successfully adapted and integrated into resource-constrained settings.
A major focus of the congress was evaluating international clinical practice guidelines (such as ESMO and NCCN standards) and discussing realistic adaptations for regions with limited diagnostic infrastructure or funding constraints.
Sessions explored the expanding role of precision oncology, immunotherapy efficacy, targeted therapies, and the integration of novel biomarkers into routine pathology workflows.
Comprehensive updates were presented across major cancer types, including:
- Gastrointestinal and Hepatobiliary Cancers
- Genitourinary Cancers
- Breast Oncology and Gynecological Tumors
- Lung Cancer and Thoracic Malignancies
- Rare Tumors and Sarcomas.
You can also read: Phase 3 ENERGIZE Trial: Final Results of Perioperative Nivolumab With Neoadjuvant Chemotherapy in MIBC
